In vitro photodynamic inactivation of Candida species and mouse fibroblasts with phenothiazinium photosensitisers and red light

Photodiagnosis and Photodynamic Therapy

Volumn 10, Issue 2, 2013, Pages 141-149

  Rodrigues, Gabriela B ^a   Dias Baruffi, Marcelo ^a   Holman, Natalie ^b   Wainwright, Mark ^b   Braga, Gilberto U L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Candida spp.; Methylene blue derivatives; Photoantimicrobial; Photodynamic antimicrobial chemotherapy

Indexed keywords

METHYLENE BLUE; PHENOTHIAZINIUM; PHOTOSENSITIZING AGENT; TOLUIDINE DERIVATIVE; UNCLASSIFIED DRUG; PHENOTHIAZINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CANDIDA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; FIBROBLAST; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RED LIGHT; ANIMAL; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ILLUMINATION; MICROBIAL VIABILITY; PHOTOCHEMOTHERAPY; PROCEDURES; RADIATION RESPONSE;

CANDIDA; CANDIDA PARAPSILOSIS; ISSATCHENKIA ORIENTALIS; MAMMALIA;

ANIMALS; CANDIDA; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FIBROBLASTS; LIGHTING; MICE; MICROBIAL VIABILITY; PHENOTHIAZINES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 84879271078     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2012.11.004     Document Type: Article

References (40)

1. Garber G. An overview of fungal infections. Drugs 2001, 61(Suppl. 1):1-12.
2. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Critical Reviews in Microbiology 2010, 36:1-53.
3. Nucci M., Queiroz-Telles F., Tobón A.M., Restrepo A., Colombo A.L. Epidemiology of opportunistic fungal infections in Latin America. Clinical Infectious Diseases 2010, 51:561-570.
4. Jayatilake J.A. A review of the ultrastructural features of superficial candidiasis. Mycopathologia 2011, 171:235-250.
5. Ruhnke M., Rickerts V., Cornely O.A., Buchheidt D., Glockner A., Heinz W., et al. Diagnosis and therapy of Candida infections: joint recommendations of the German speaking mycological society and the Paul-Ehrlich-Society for Chemotherapy. Mycosis 2011, 54:279-310.
6. Leigh J., Shetty K., Fidel P. Oral opportunistic infections in HIV-positive individuals: review and role of mucosal immunity. AIDS Patient Care and STDS 2004, 18:443-456.
7. Kim J., Sudbery P. Candida albicans a major human fungal pathogen. Journal of Microbiology 2011, 49:171-177.
8. Wright S.C., Maree J.E., Sibanyoni M. Treatment of oral thrush in HIV/AIDS patients with lemon juice and lemon grass (Cymbopogon citratus) and gentian violet. Phytomedicine 2009, 16:118-124.
9. Motta A.L., de Almeida G.M.D., de Almeida Júnior J.N., Nascimento Burattini M., Rossi F. Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex. Brazilian Journal of Infectious Diseases 2010, 14:441-448.
10. Rex J.H., Rinaldi M.G., Pfaller M.A. Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy 1995, 39:1-8.
11. Pelletier R., Peter J., Antin C., Gonzalez C., Wood L., Walsh T.J. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. Journal of Clinical Microbiology 2000, 38:1563-1568.
12. Martel C.M., Parker J.E., Bader O., Weig M., Gross U., Warrilow A.G.S., et al. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14α-demethylase) and ERGG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrobial Agents and Chemotherapy 2010, 54:3578-3583.
13. Sangamwar A.T., Deshpande U.D., Pekamwar S.S. Antifungals: need to search for a new molecular target. Indian Journal of Pharmaceutical Sciences 2008, 70:423-430.
14. Patton L.L., Bonito A.J., Shugars D.A. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 2001, 92:170-179.
15. Donnelly R.F., McCarron P.A., Tunney M.M. Antifungal photodynamic therapy. Microbiological Research 2008, 163:1-12.
16. Lyon J.P., Moreira L.M., de Moraes P.C.G., Vieira dos Santos F., Aparecida de Resende M. Photodynamic therapy for pathogenic fungi. Mycoses 2011, 54:e265-e271.
17. Wainwright M., Crossley K. Methylene Blue - a therapeutic dye for all seasons?. Journal of Chemotherapy 2002, 14:431-443.
18. Dai T., de Arce V.J.B., Tegos G.A., Hamblin M.R. Blue dye and red light, a dynamic combination for prophylaxis and treatment of cutaneous Candida albicans infection in mice. Antimicrobial Agents and Chemotherapy 2011, 48:5710-5717.
19. Wilson M., Mia N. Sensitization of Candida albicans to killing by low-power laser light. Journal of Oral Pathology and Medicine 1993, 22:354-357.
20. Paardekooper M., De Bruijne A.W., Van Stevenick J., Van den Broek P.J. Intracellular damage in yeast cells caused by photodynamic treatment with toluidine blue. Photochemistry and Photobiology 1995, 61:84-89.
21. Teichert M.C., Jones J.W., Usacheva M.N., Biel M.A. Treatment of oral candidiasis with methylene blue-mediated photodynamic therapy in an immunodeficient murine model. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2002, 93:155-160.
22. de Souza S.C., Junqueira J.C., Balducci I., Koga-Ito C.Y., Munin E., Jorge A.O.C. Photosensitization of different Candida species by low-power laser light. Journal of Photochemistry and Photobiology B 2006, 83:34-38.
23. Martins J.S., Junqueira J.C., Faria R.L., Fonseca Santiago N., Rossoni R.D., Dias Colombo C.E., et al. Antimicrobial photodynamic therapy in rat experimental candidiasis: evaluation of pathogenicity factors of Candida albicans. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 2011, 111:71-77.
24. Wainwright M., Meegan K., Loughran C., Phenothiazine Photosensitisers I.X. Tetra- and pentacyclic derivatives as photoantimicrobial agents. Dyes and Pigments 2011, 91:1-5.
25. Gonzales F.P., da Silva S.H., Roberts D.W., Braga G.U.L. Photodynamic inactivation of conidia of the fungi Metarhizium anisopliae and Aspergillus nidulans with methylene blue and toluidine blue. Photochemistry and Photobiology 2010, 86:653-661.
26. Prates R.A., Kato I.T., Ribeiro M.S., Tegos G.P., Hamblin M.R. Influence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of Candida albicans. Journal of Antimicrobial Chemotherapy 2011, 66:1525-1532.
27. Gonzales F.P., Maisch T. Photodynamic inactivation for controlling Candida albicans infection. Fungal Biology 2012, 116:1-10.
28. Wainwright M., Mohr H., Walker W. Phenothiazinium derivatives for pathogen inactivation in blood products. Journal of Photochemistry and Photobiology B 2007, 86:45-58.
29. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard 2008, Clinical and Laboratory Standards Institute, Wayne, PA, CLSI document M27-A3. 3rd ed.
30. Souza R.C., Junqueira J.C., Rossoni R.D., Pereira C.A., Munin E., Jorge A.O. Comparison of the photodynamic fungicidal efficacy of methylene blue, toluidine blue, malachite green and low-power laser irradiation alone against Candida albicans. Lasers in Medical Science 2010, 25:385-389.
31. Jackson Z., Meghji S., McRobert A., Henderson B., Wilson M. Killing of the yeast and hyphal forms of Candida albicans using a light-activated antimicrobial agent. Lasers in Medical Science 1999, 14:150-157.
32. Soares B.M.D.L., da Silva D.L.G.R., Sousa G.R., Amorim J.C.F., Aparecida de Resende M., Pinotti M., et al. In vitro photodynamic inactivation of Candida spp. growth and adhesion to buccal epithelial cells. Journal of Photochemistry and Photobiology B 2009, 94:65-70.
33. Bliss J.M., Bigelow C.E., Foster T.H., Haidaris C.G. Susceptibility of Candida species to photodynamic effects of photofrin. Antimicrobial Agents and Chemotherapy 2004, 48:2000-2006.
34. Zeina B., Greenman J., Corry D., Purcell W.M. Cytotoxic effects of antimicrobial photodynamic therapy on keratinocytes in vitro. British Journal of Dermatology 2002, 146:568-573.
35. Xu Y., Young M.J., Battaglino R.A., Morse L.R., Fontana C.R., Pagonis T.C., et al. Endodontic antimicrobial photodynamic therapy: safety assessment in mammalian cell cultures. Journal of Endodontics 2009, 35:1567-1572.
36. Tanaka M., Kinoshita M., Yoshihara Y., Shinomiya N., Seki S., Nemoto K., et al. Optimal photosensitizers for photodynamic therapy of infections should kill bacteria but spare neutrophils. Photochemistry and Photobiology 2012, 88:227-232.
37. Lambrechts S.A.G., Schwartz K.R., Aalders M.C.G., Dankert J.B. Photodynamic inactivation of fibroblasts by a cationic porphyrin. Lasers in Medical Science 2005, 20:62-67.
38. Machado A.H.A., Moraes K.C.M., Soares C.P., Pelisson M.M.M., Beltrame M., da Silva N.S. Photodynamic therapy with a new photosensitizing agent. Photomedicine and Laser Surgery 2007, 25:220-228.
39. Wainwright M., Giddens R.M. Phenothiazinium photosensitisers: choices in synthesis and application. Dyes Pigments 2003, 57:245-257.
40. Wainwright M. Championing photoantimicrobial discovery. Photodiagnosis and Photodynamic Therapy 2011, 8:288-289.